Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

NASDAQ:FENC

Fennec Pharmaceuticals Inc.

Last Close

9.16

26/04 20:00

Market Cap

263.68M

Beta: 0.16

Volume Today

153.48K

Avg: 80.91K

PE Ratio

−11.72

PFCF: −16.43

Please Sign In To Use The Chat